Rational selection of antigenic targets for Group A Streptococcus vaccine: updates, challenges and opportunities

Area of Science:

• Microbiology
• Immunology
• Vaccinology

Background:

• Group A Streptococcus (GAS) causes significant global mortality, exceeding 500,000 deaths annually.
• Despite extensive research for nearly a century, a licensed GAS vaccine remains unavailable.
• Key obstacles include GAS antigenic diversity, intricate host-pathogen interactions, potential autoimmunity, and undefined protection correlates.

Purpose of the Study:

• To review recent advancements in Group A Streptococcus vaccine development.
• To identify and discuss the primary challenges hindering GAS vaccine licensure.
• To outline criteria and emerging opportunities for selecting optimal GAS vaccine antigens.

Main Methods:

• Literature review of recent scientific publications on GAS vaccine research.
• Analysis of challenges including antigenic variation, host immunity, and safety concerns.
• Exploration of novel approaches and criteria for antigen discovery and selection.

Main Results:

• Recent research has yielded promising vaccine candidates and strategies.
• Significant hurdles persist, including managing antigenic diversity and preventing autoimmune reactions.
• Clear correlates of protection are yet to be established for GAS vaccines.

Conclusions:

• Developing an effective GAS vaccine requires overcoming substantial scientific and immunological challenges.
• Strategic antigen selection, informed by new criteria and opportunities, is crucial for future vaccine success.
• Continued research into host-pathogen interactions and immune responses is essential for GAS vaccine advancement.